(Q35553970)

8 August 2017

Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect (English)

1 reference

8 August 2017

3

Klareskog L

1 reference

8 August 2017

2

Brannemark S

1 reference

8 August 2017

van Vollenhoven RF

1

1 reference

PubMed ID

15020338

8 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

Annals of the Rheumatic Diseases

8 August 2017

1 reference

8 August 2017

63

1 reference

8 August 2017

4

1 reference

8 August 2017

426-430

1 reference

Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment

8 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754945

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754945

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754945

Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754945

Limitations of randomized controlled clinical trials to depict accurately long-term outcomes in rheumatoid arthritis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754945

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754945

Development of a disease activity score based on judgment in clinical practice by rheumatologists.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754945

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1754945

The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial

26 September 2018

1 reference

12 December 2020

Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH

1 reference

12 December 2020

How much of the placebo 'effect' is really statistical regression?

1 reference

12 December 2020

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.2003.010967

1 reference

8 August 2017

1 reference

8 August 2017

1 reference

PubMed ID

15020338